Skip to main content

Genital Nullification — AFAB (HBSO + Colpectomy + Vulvectomy + Perineal Urethrostomy)

Genital nullification for AFAB individuals is an individually customised gender-affirming procedure combining hysterectomy with bilateral salpingo-oophorectomy (HBSO), colpectomy (vaginectomy), vulvectomy, and perineal urethrostomy (PU) — resulting in a smooth perineal surface devoid of external or internal genital structures.[1][2] Most commonly sought by nonbinary or agender individuals who experience dysphoria related to all natal genital anatomy and do not desire masculinizing genital reconstruction (phalloplasty or metoidioplasty).[1][3]

This is the dedicated atlas page. For the broader variant-GGAS framework, see Non-Binary / Nullification Gender-Affirming Surgery. The four component procedures live on dedicated atlas pages — see Gender-Affirming Hysterectomy, Vaginectomy / Colpectomy, and the 7-Flap Perineal Urethrostomy / Blandy Perineal Urethrostomy canonical pages. For the AMAB counterpart, see Genital Nullification — AMAB.

Published data specifically on the complete AFAB nullification combination are extremely limited — most evidence must be synthesised from the individual component procedures. The Ascha 2024 individually-customised-procedures series (n = 16) is the central GAS-specific reference.[1]

Surgical Overview and Staging​

May be performed as single-stage or multi-stage depending on surgeon preference, patient factors, and institutional protocols. Standard masculinising-GAS staging is: (1) HBSO ± chest, (2) colpectomy with genital reconstruction, (3) prosthetic implantation.[4] For nullification, the absence of phalloplasty / metoidioplasty simplifies the surgical plan, and Kim-Ortega 2025 demonstrated concurrent HBSO + colpectomy adds no significant clinical morbidity vs staged.[5]

Component 1 — HBSO​

Full technique detail on the Gender-Affirming Hysterectomy atlas page.

Key technique considerations specific to this population:[6][7][8][9]

  • Vaginal atrophy — long-term testosterone causes mucosal atrophy and narrowing; laparoscopic approaches provide superior visualisation vs vaginal hysterectomy.
  • Two-layer vaginal-cuff closure recommended to reduce cuff complications; preferred for patients with pelvic-organ dysphoria.
  • Adequate infundibulopelvic-ligament margin — minimises ovarian-remnant syndrome risk; persistent ovarian tissue → menstruation = profoundly dysphoria-inducing.
  • Preoperative pelvic exam may be omitted without adverse perioperative outcomes (Murphy 2023 n = 62) — reduces dysphoria barriers to care.[10]

Outcomes — Siringo / Bretschneider NSQIP n = 40,742 demonstrated trans-male status not independently associated with complications, with comparable rates to benign hysterectomy.[11]

Fertility counselling — irreversibility of oophorectomy; offer fertility-preservation consultation prior to surgery.[8][12][13]

Component 2 — Colpectomy (Vaginectomy)​

The most technically demanding component with the highest complication rate of the four. Full 4-variant technique detail (transperineal sharp excision / fulguration / RALV / laparoscopic vaginal-assisted) on the Vaginectomy / Colpectomy atlas page.

Critical distinction for nullification context: AVW flap preservation for UL is not required (no phalloplasty / metoidioplasty target) — fulguration is therefore an attractive choice given its lower morbidity (Ho 2025: EBL 88 vs 254 mL p < .05; OR 183 vs 290 min p < .05; equivalent fistula and recurrence).[15] Where transperineal sharp excision is preferred (e.g., concerns about persistent vaginal remnants in fulgurated cohorts), the Hougen 2020 transperineal-approach technique paper is the canonical reference.[16]

Groenman 2017 RALC as a single-step procedure combined with robotic TLH-BSO (n = 36): median EBL 75 mL; median OR time 230 min; median discharge 3 d; 1 major complication (postoperative bleeding requiring transfusion).[17]

Colpectomy complications (Nikkels 2019 n = 143 — largest series)[14]​

ComplicationIncidence
Major perioperative (bowel / ureter / bladder injury, hemorrhage with transfusion)10%
Major postoperative (hemorrhage, hematoma, fistula, wound infection, prolonged pain)12%
Minor postoperative (UTI, urinary retention, minor hemorrhage)35%
Peritoneal entry (transperineal)44% (closed primarily without sequelae)
Vaginal remnant recurrence5–8%
Vagino-cutaneous fistula10% (equal excision vs fulguration)

Nikkels: vaginal colpectomy has a "high complication rate, but its advantages seem to outweigh its disadvantages" — in all but one case, no long-term sequelae.[14]

Component 3 — Vulvectomy​

In the nullification context, removal of the labia majora, labia minora, clitoral hood, and clitoris to achieve a smooth perineal contour. Least well-described component in the GAS literature. Vulvectomy is listed as a recognised gender-affirming procedure (ICD-9 71.62) in temporal trends analyses of GAS.[2]

Key surgical considerations:

  • Clitorectomy is the most consequential aspect — permanently eliminates the primary source of erogenous sensation. Extensive preoperative counselling regarding the irreversibility of this loss is essential.
  • Wound closure / perineal contouring — after vulvar-structure removal, remaining skin edges approximated for a flat perineum. Techniques adapted from oncologic vulvar reconstruction include V-Y advancement flaps, medial thigh fasciocutaneous flaps, and gluteal-fold flaps for larger defects or tension-free approximation.[18][19]
  • Urethral-meatus management — the native AFAB meatus sits within the vestibule; after vulvectomy removes the vestibular tissue surrounding the meatus, the urethra must be brought to the perineal skin surface as a PU (Component 4).

Component 4 — Perineal Urethrostomy​

In AFAB nullification, the PU differs from the AMAB context because the native AFAB urethra is already short (~4 cm). After vulvectomy removes the vestibular tissue surrounding the native meatus, the urethra is matured to the new perineal skin surface.

Key technical principles (adapted from reconstructive urology and oncologic surgery):[20][21]

  • Urethra spatulated and sutured to perineal skin with interrupted absorbable sutures to create a widely patent stoma.
  • Preservation of urethral blood supply is critical to prevent stenosis.[21]
  • Stoma calibrated to at least 24–30 Fr to minimise stenosis risk.[22]
  • Urethral catheter or suprapubic tube maintained postoperatively (typically 10–21 d).

See canonical PU pages for full technique:

PU outcomes (extrapolated from reconstructive-urology literature)[20][21]​

  • Success rate (freedom from re-intervention) 83–95%.
  • Stenosis rate 5–18%; most within first 18 mo.
  • Patient satisfaction 84–86%.
  • 76% unbothered by seated voiding.[20]

AFAB-specific stenosis-risk consideration: the shorter native urethra and absence of prior radiation (strongest stenosis risk factor, OR 11.2) may confer lower stenosis risk than reported in the predominantly cisgender male PU literature.[21]

Urinary Function Considerations Specific to AFAB Anatomy​

The AFAB urethra is anatomically shorter and lacks a sphincteric mechanism equivalent to the male external sphincter. After vulvectomy and PU:

  • Continence depends on intact bladder neck and pelvic-floor musculature. Pelvic-floor dysfunction affects up to 94.1% of transgender men — pre- and post-operative pelvic-floor PT is essential.[23]
  • Urethral complications in transmasculine surgery (phalloplasty / metoidioplasty) primarily arise from urethral lengthening — fistula 15–60%, stricture 25–58%. Nullification does NOT involve UL, which should substantially reduce these risks.[23]
  • UTI risk may be increased due to altered anatomy and shortened urethral path.[24]

Lifelong Postoperative Care​

Hormone replacement (mandatory after BSO)[8][12][25]​

  • Testosterone (if previously on masculinising therapy) — adequate doses prevent bone demineralisation. No increased cardiovascular events reported in transmasculine individuals on testosterone.[8]
  • Estrogen (if not on testosterone) — standard menopausal HRT protocols.
  • No hormone therapy — significant osteoporosis, cardiovascular, and metabolic-syndrome risk. Endocrine Society recommends DEXA bone-mineral-density monitoring after gonadectomy if HRT discontinued.[12]

ACOG framing: while many patients do not plan to stop testosterone, some may do so due to access issues — counsel about risks and benefits of ovarian preservation even in patients planning to continue testosterone.[8]

Cancer screening​

After HBSO and colpectomy, cervical cancer screening is no longer needed (cervix removed). If vaginal-remnant tissue persists, surveillance may be warranted.[24]

PU surveillance​

Regular follow-up first 1–2 years for stenosis; most stenoses present within 18 mo.[21]

Pelvic-floor rehabilitation​

Pre- and post-operative pelvic-floor PT to optimise continence and voiding.[23]

Psychological Outcomes and Satisfaction​

Nullification-specific data lacking; broader GAS evidence:

  • Almazan / Keuroghlian US Transgender Survey — GAS associated with lower psychological distress (aOR 0.58), lower suicidal ideation (aOR 0.56), lower smoking (aOR 0.65).[26]
  • Pletta 2025 — reproductive surgeries (including gonadectomy) consistently rated most satisfactory across all gender-identity groups (mean 4.6/5); nonbinary AFAB specifically 4.4/5.[27]
  • Cooney 2025 SR (13 studies) — all 4 QoL studies showed statistically significant improvement; all 5 dysphoria studies showed improved gender congruence.[28]
  • Postoperative regret across GAS consistently < 1–3%.[29]

Access and Insurance​

AFAB genital nullification remains extremely rare — offered by very few surgical centres. Only 33.9% of nonbinary AFAB individuals have received any form of GAS (vs 58.3% of transgender men).[27] Insurance coverage for nonbinary-specific procedures is variable and often more challenging to obtain than for standard binary surgical pathways.[1]

Summary — Risk Profile by Component​

ComponentOR timeEBLMajor complication rateKey long-term risk
HBSO (laparoscopic)60–90 minMinimal~ 3–4% (Bretschneider parity)[11]Ovarian-remnant syndrome; need for HRT
Colpectomy (excision)112–135 min250–300 mL10% perioperative; 12% postoperative[14]Vaginal remnant 5–8%; fistula 10%
Colpectomy (fulguration)~ 183 min (combined)88 mLSimilar fistula (10%)[15]Vaginal remnant 5%
VulvectomyVariableVariableWound dehiscence, infectionPermanent loss of erogenous sensation (irreversible)
Perineal urethrostomy30–60 min (est.)Minimal5–6%Stomal stenosis 5–18%[20][21]

Evidence Limitations​

  • No nullification-specific outcomes series in AFAB — all evidence is synthesised from component-procedure data.[1]
  • Ascha 2024 (n = 16) is the central individually-customised reference but does not provide AFAB-nullification-specific subgroup outcomes.[1]
  • PU outcomes data in this population extrapolated from cisgender reconstructive-urology / oncologic literature — younger AFAB patients without radiation history may have lower stenosis risk than that benchmark.[20][21]
  • Vulvectomy is the least-described component — no GAS-specific outcomes series; technique principles adapted from oncologic vulvar reconstruction.[18][19]
  • Validated nullification-specific PROMs lacking in the nonbinary AFAB population — Oles 2022 documents the broader transgender-PROM gap.[29]

References​

1. Ascha M, Rigsby S, Shoham M, et al. Individually customized gender-affirming genital procedures: techniques and considerations. J Sex Med. 2024;21(9):827–834. doi:10.1093/jsxmed/qdae075

2. Canner JK, Harfouch O, Kodadek LM, et al. Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg. 2018;153(7):609–616. doi:10.1001/jamasurg.2017.6231

3. Claeys W, Wolff DT, Zachou A, et al. Variant genital gender-affirming surgery: a systematic review. BJU Int. 2025;135(1):40–53. doi:10.1111/bju.16513

4. Berli JU, Knudson G, Fraser L, et al. What surgeons need to know about gender confirmation surgery when providing care for transgender individuals: a review. JAMA Surg. 2017;152(4):394–400. doi:10.1001/jamasurg.2016.5549

5. Kim-Ortega Y, Taboada MP, Ivanenko PT, Weinstein MM. Gender-affirming vaginectomy with concurrent hysterectomy compared to staged vaginectomy after hysterectomy: a cohort study analysis of 30-day perioperative outcomes. Int Urogynecol J. 2025;36(4):875–880. doi:10.1007/s00192-025-06112-2

6. Marfori CQ, Wu CZ, Katler Q, et al. Hysterectomy for the transgendered male: review of perioperative considerations and surgical techniques with description of a novel 2-port laparoscopic approach. J Minim Invasive Gynecol. 2018;25(7):1149–1156. doi:10.1016/j.jmig.2017.09.008

7. Simko S, Popa O, Stuparich M. Gender-affirming care for the minimally invasive gynecologic surgeon. Curr Opin Obstet Gynecol. 2024;36(4):301–312. doi:10.1097/GCO.0000000000000956

8. Committee on Gynecologic Practice and Committee on Health Care for Underserved Women. Health care for transgender and gender diverse individuals: ACOG Committee Opinion, Number 823. Obstet Gynecol. 2021;137(3):e75–e88. doi:10.1097/AOG.0000000000004294

9. Lee Cruz AS, Cruz J, Behbehani S, et al. Hysterectomy and oophorectomy for transgender patients: preoperative and intraoperative considerations. J Minim Invasive Gynecol. 2024;31(4):265–266. doi:10.1016/j.jmig.2023.12.009

10. Murphy EC, Kim Y, Weinstein MM. Omission of pelvic examination before gender-affirming hysterectomy and vaginectomy. Obstet Gynecol. 2023;141(6):1160–1162. doi:10.1097/AOG.0000000000005189

11. Siringo NV, Boczar D, Berman ZP, et al. Gender-affirming hysterectomy in the United States: a comparative outcomes analysis and potential implications for uterine transplantation. Perspect Sex Reprod Health. 2023;55(4):222–228. doi:10.1363/psrh.12246

12. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi:10.1210/jc.2017-01658

13. Carbonnel M, Karpel L, Cordier B, Pirtea P, Ayoubi JM. The uterus in transgender men. Fertil Steril. 2021;116(4):931–935. doi:10.1016/j.fertnstert.2021.07.005

14. Nikkels C, van Trotsenburg M, Huirne J, et al. Vaginal colpectomy in transgender men: a retrospective cohort study on surgical procedure and outcomes. J Sex Med. 2019;16(6):924–933. doi:10.1016/j.jsxm.2019.03.263

15. Ho P, Schmidt-Beuchat E, Sljivich M, et al. Impact of vaginectomy technique on the outcomes of transmasculine gender-affirming surgery. J Sex Med. 2025:qdaf148. doi:10.1093/jsxmed/qdaf148

16. Hougen HY, Shoureshi PS, Sajadi KP. Gender-affirming vaginectomy — transperineal approach. Urology. 2020;144:263–265. doi:10.1016/j.urology.2020.05.084

17. Groenman F, Nikkels C, Huirne J, van Trotsenburg M, Trum H. Robot-assisted laparoscopic colpectomy in female-to-male transgender patients: technique and outcomes of a prospective cohort study. Surg Endosc. 2017;31(8):3363–3369. doi:10.1007/s00464-016-5333-8

18. John HE, Jessop ZM, Di Candia M, et al. An algorithmic approach to perineal reconstruction after cancer resection — experience from two international centers. Ann Plast Surg. 2013;71(1):96–102. doi:10.1097/SAP.0b013e3182414485

19. Persichetti P, Simone P, Berloco M, et al. Vulvo-perineal reconstruction: medial thigh septo-fascio-cutaneous island flap. Ann Plast Surg. 2003;50(1):85–89. doi:10.1097/00000637-200301000-00015

20. Joshi EG, VanDyke ME, Langford BT, Franzen BP, Morey AF. Algorithmic midline approach to perineal urethrostomy is associated with long-term success and high patient satisfaction. Urology. 2024;190:133–139. doi:10.1016/j.urology.2024.03.016

21. Myers JB, Porten SP, McAninch JW. The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply. Urology. 2011;77(5):1223–1227. doi:10.1016/j.urology.2010.10.041

22. French D, Hudak SJ, Morey AF. The "7-flap" perineal urethrostomy. Urology. 2011;77(6):1487–1489. doi:10.1016/j.urology.2010.10.053

23. Motiwala ZY, Misra S, Desai A, et al. Postoperative urogynecologic complications after gender-affirming surgery: a narrative review. Int Urogynecol J. 2026;37(4):805–822. doi:10.1007/s00192-025-06405-6

24. Jackson Q, Yedlinsky NT, Gray M. Lifelong care of patients after gender-affirming surgery. Am Fam Physician. 2024;109(6):560–565.

25. Reilly ZP, Fruhauf TF, Martin SJ. Barriers to evidence-based transgender care: knowledge gaps in gender-affirming hysterectomy and oophorectomy. Obstet Gynecol. 2019;134(4):714–717. doi:10.1097/AOG.0000000000003472

26. Almazan AN, Keuroghlian AS. Association between gender-affirming surgeries and mental health outcomes. JAMA Surg. 2021;156(7):611–618. doi:10.1001/jamasurg.2021.0952

27. Pletta DR, Quint M, Radix AE, et al. Gender-affirming surgical history, satisfaction, and unmet needs among transgender adults. JAMA Netw Open. 2025;8(9):e2532494. doi:10.1001/jamanetworkopen.2025.32494

28. Cooney EE, Muschialli L, Yeh PT, et al. Provision of gender-affirming care for trans and gender-diverse adults: a systematic review of health and quality-of-life outcomes, values and preferences, and costs. EClinicalMedicine. 2025;88:103458. doi:10.1016/j.eclinm.2025.103458

29. Oles N, Darrach H, Landford W, et al. Gender-affirming surgery: a comprehensive, systematic review of all peer-reviewed literature and methods of assessing patient-centered outcomes (Part 2: genital reconstruction). Ann Surg. 2022;275(1):e67–e74. doi:10.1097/SLA.0000000000004717